Menu
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
• Study to evaluate potential of novel combination therapy for hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer (mBC)
• Boehringer Ingelheim's IGF mAB BI 836845 and Lilly's CDK 4 and 6 inhibitor abemaciclib have shown promising early phase results in metastatic breast cancer
(BUSINESS WIRE)-- Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced a new collaboration on a Phase 1b study that will evaluate the safety and tolerability of BI 836845, Boehringer Ingelheim's insulin-like growth factor (IGF)-1/IGF-2 ligand neutralising antibody, in combination with abemaciclib (LY2835219), Lilly's cyclin-dependent kinase (CDK) 4 and 6 inhibitor, in patients diagnosed with HR+/HER2- mBC. ...
Source : http://me-newswire.net//news/18332/en...
Mercredi 19 Novembre 2025 - 15:00 Algérie : la BAD salue les grands chantiers lancés |
Mercredi 5 Novembre 2025 - 18:21 Tchad : Star Oil Tchad et Airtel Money s'allient pour accélérer l'inclusion financière |
Mardi 28 Octobre 2025 - 19:45 Tchad : Atelier de Formation sur l'Utilisation des Images par le Volet des Standards des Ménages (EHCVM) |
